| 產品名稱 |
1F5 |
| 商品貨號 |
B163622 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications |
The antibody is specific for CD20 (expressed on normal and neoplastic human B cells) and can induce proliferation of resting B cells. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against human CD20 B cell antigen (Bp35) |
| Cellular Products |
immunoglobulin; monoclonal antibody; against human CD20 B cell antigen (Bp35) |
| Comments |
The antibody is specific for CD20 (expressed on normal and neoplastic human B cells) and can induce proliferation of resting B cells. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Culture Conditions |
Temperature: 37.0°C |
| Isotype |
IgG2a |
| Name of Depositor |
Bristol-Myers Co. |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Senter PD, et al. Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells. US Patent 4,975,278 dated Dec 4 1990
Clark EA, et al. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc. Natl. Acad. Sci. USA 82: 1766-1770, 1985. PubMed: 3872456
|
